NCT01922765

Concomitant Therapy of H. Pylori

Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 540 (estimated)
• Sponsor: The Catholic University of Korea · Academic / Other
• Sex: All
• Age: 19 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

If we compare eradication rate of Helicobacter pylori divided to 4 groups: amoxicillin, rabeprazole, clarithromycin(AOC), amoxicillin, rabeprazole, metronidazole(AOM), treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days(sequential), amoxicillin, clarithromycin, metronidazole, rabeprazole(concomitant), then the eradication rate of concomitant group will be the highest.

Detailed description

* Subject: The patient of gastritis, gastric ulcer, and duodenal ulcer infected with Helicobacter pylori * 170 subjects per group * Eradication regimens are as follows: AOC group, treated with amoxicillin, rabeprazole, clarithromycin for 7 days; AOM group, treated with amoxicillin, rabeprazole, metronidazole for 7 days; sequential group, treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days; concomitant group, treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days

Conditions

• Gastritis, Gastric Ulcer, and Duodenal Ulcer

Interventions

Type	Name	Description
DRUG	amoxicillin, clarithromycin, metronidazole, rabeprazole

Timeline

• Start date: 2013-08-01
• Primary completion: 2014-02-01
• Completion: 2014-02-01
• First posted: 2013-08-14
• Last updated: 2014-02-11

Locations

1 site across 1 country: South Korea